Purchase this article with an account.
Kaweh Mansouri; Safety and Efficacy of High-Intensity Focused Ultrasound Cyclocoagulation in Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6129.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate safety and efficacy of High-Intensity Focused Ultrasound (HIFU) Cyclocoagulation for treatment of refractory glaucoma.
15 glaucoma patients underwent IOP-lowering treatment with (UC3, EyeTechCare, France) in a prospective manner. All interventions were performed under general anesthesia. Success was defined as an IOP reduction of >20% from baseline.
Mean age of study population was 42 ± 10.2 years (67% women). Main diagnosis was neovascular glaucoma (n=5), followed by primary open angle glaucoma (n=4) and different forms of secondary glaucoma (n=6). Baseline IOP was 31.6±5.7 mmHg. After HIFU treatment, IOP was 25.2±6.5 mmHg, 22.0±9.4 mmHg, 20.9± 6.3 mmHg, 24.2±11.5 mmHg and 23.3±11.7 mmHg at day 1, week 1, month 1, month 6 and 1 year, respectively. The average IOP reduction from baseline was -29%.<br /> Data from 9 out of 15 patients were available at the 1-year follow-up visit. Among these, 5 (56%) were considered as successful. No serious adverse events were recorded.
HIFU seems to be an efficient and safe treatment for eyes with refractory glaucoma.
This PDF is available to Subscribers Only